Hostname: page-component-f554764f5-nwwvg Total loading time: 0 Render date: 2025-04-11T00:05:06.682Z Has data issue: false hasContentIssue false
  • English
  • Français

Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial

Published online by Cambridge University Press:  14 January 2013

Andrew J. Cutler ,
Amir H. Kalali ,
Greg W. Mattingly ,
Jelena Kunovac  and
Xiangyi Meng
Andrew J. Cutler*
Affiliation:
Department of Psychiatry, University of Florida, Bradenton, Florida, USA Florida Clinical Research Center, LLC, Bradenton, Florida, USA
Amir H. Kalali
Affiliation:
University of California, San Diego, California, USA Medical and Scientific Services and CNS Global Therapeutic Team, Quintiles, Inc., San Diego, California, USA
Greg W. Mattingly
Affiliation:
Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA St. Charles Psychiatric Associates, St. Charles, Missouri, USA
Jelena Kunovac
Affiliation:
Excell Research, Oceanside, California, USA Altea Research, Las Vegas, Nevada, USA
Xiangyi Meng
Affiliation:
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
*
*Address for correspondence: Andrew J. Cutler, MD, Courtesy Assistant Professor, Department of Psychiatry, University of Florida, 8043 Cooper Creek Blvd., Suite 107, Bradenton, FL 34201, USA. (Email [email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Introduction/Objective

Long-term use of the atypical antipsychotic iloperidone has not been investigated at doses above 16 mg/d. This article describes safety and tolerability results from the 25-week open-label extension of a 4-week placebo- and ziprasidone-controlled clinical trial of iloperidone.

Methods

Patients received a dose of 24 mg/d (given as 12 mg twice daily; mean dose = 21.6 mg) that could be reduced to 12 mg/d (given once daily at bedtime) any time after day 35 at the investigator's discretion.

Results

A total of 72/173 patients (41.6%) completed the open-label extension. Treatment-emergent adverse events (TEAEs), most mild to moderate in severity, included headache (13.9%), weight increase (9.2%), dizziness (6.9%), nausea (6.4%), sedation (6.4%), and insomnia (5.2%). The only notable dose-related TEAEs were increased weight and headache. Levels of serum glucose, lipids, and prolactin were essentially unchanged or decreased during treatment. In general, akathisia and extrapyramidal symptoms (EPS) improved or were unchanged during treatment. There was no signal of worsening of efficacy based on changes from baseline in the Positive and Negative Syndrome Scale-Total.

Discussion/Conclusion

This study further supports the long-term safety and tolerability of iloperidone for the treatment of schizophrenia, including iloperidone's favorable effect on metabolic laboratory parameters and low propensity to cause akathisia or EPS.

Keywords

atypical antipsychoticschizophreniaonce-daily dosingakathisiaextrapyramidal symptomsPANSS-T scores
Type
Original Research
Information
CNS Spectrums , Volume 18 , Issue 1 , February 2013 , pp. 43 - 54
Copyright
Copyright © Cambridge University Press 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

Footnotes

This clinical study was funded by Vanda Pharmaceuticals. Assistance with manuscript preparation was provided by Oxford PharmaGenesis, Inc., and this assistance was funded by Novartis Pharmaceuticals Corporation. The authors would also like to acknowledge project management support to Novartis provided by Arlene Kaufman of Research Pharmaceuticals, Inc. The authors wish to acknowledge the significant contributions of Dr. Paolo Baroldi and Rebecca Lannan, formerly of Vanda Pharmaceuticals, and of Dr. Curt Wolfgang and Jennifer Hamilton of Vanda Pharmaceuticals.

References

1.McEvoy, JP. The costs of schizophrenia. J Clin Psychiatry. 2007; 68(Suppl 14): 4–7.Google ScholarPubMed
2.Rössler, W, Salize, HJ, van Os, J, etal. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol. 2005; 15: 399–409.CrossRefGoogle ScholarPubMed
3.Potkin, SG, Litman, RE, Torres, R, Wolfgang, CD. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol. 2008; 28(2 Suppl 1): S4–S11.CrossRefGoogle ScholarPubMed
4.Cutler, AJ, Kalali, AH, Weiden, PJ, etal. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008; 28(2 Suppl 1): S20–S28.CrossRefGoogle ScholarPubMed
5.Weiden, PJ, Cutler, AJ, Polymeropoulos, MH, etal. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol. 2008; 28(2 Suppl 1): S12–S19.CrossRefGoogle ScholarPubMed
6.Kane, JM, Lauriello, J, Laska, E, etal. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol. 2008; 28(2 Suppl 1): S29–S35.CrossRefGoogle ScholarPubMed
7.Chouinard, G, Margolese, HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res. 2005; 76(2–3): 247–265.CrossRefGoogle ScholarPubMed
8.Barnes, TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989; 154: 672–676.CrossRefGoogle ScholarPubMed
9.Breier, A, Berg, PH, Thakore, JH, etal. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry. 2005; 162: 1879–1887.CrossRefGoogle ScholarPubMed
10.Kane, JM, Osuntokun, O, Kryzhanovskaya, LA, etal. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. J Clin Psychiatry. 2009; 70: 572–581.CrossRefGoogle ScholarPubMed
11.Simpson, GM, Weiden, P, Pigott, T, etal. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. Am J Psychiatry. 2005; 162: 1535–1538.CrossRefGoogle ScholarPubMed
12.Kinon, BJ, Lipkovich, I, Edwards, SB, etal. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J Clin Psychopharmacol. 2006; 26(2): 157–162.CrossRefGoogle ScholarPubMed
13.Kiraly, B, Gunning, K, Leiser, J. Primary care issues in patients with mental illness. Am Fam Physician. 2008; 78(3): 355–362.Google ScholarPubMed
14.McEvoy, JP, Lieberman, JA, Perkins, DO, etal. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007; 164: 1050–1060.CrossRefGoogle ScholarPubMed
15.Reynolds, GP, Zhang, Z, Zhang, X. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry. 2003; 160: 677–679.CrossRefGoogle Scholar
16.Ellingrod, VL, Perry, PJ, Ringold, JC, etal. Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine. Am J Med Genet B Neuropsychiatr Genet. 2005; 134B: 76–78.CrossRefGoogle ScholarPubMed
17.Thompson, A, Lavedan, C, Volpi, S. Absence of weight gain association with the HTR2C -759C/T polymorphism in patients with schizophrenia treated with iloperidone. Psychiatry Res. 2010; 175: 271–273.CrossRefGoogle ScholarPubMed
18.Torre, DL, Falorni, A. Pharmacological causes of hyperprolactinemia. Ther Clin Risk Manag. 2007; 3: 929–951.Google ScholarPubMed
19.Weiden, PJ. Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial. J Clin Psychiatry. 2007; 68(Suppl 1): 12–19.Google ScholarPubMed
20.Lieberman, JA, Stroup, TS, McEvoy, JP, etal. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353: 1209–1223.CrossRefGoogle ScholarPubMed
21.Weiden, PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract. 2007; 13: 13–24.CrossRefGoogle Scholar
22.Arato, M, O'Connor, R, Meltzer, HY. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol. 2002; 17: 207–215.CrossRefGoogle Scholar
23.Keks, NA, Ingham, M, Khan, A, etal. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study. Br J Psychiatr. 2007; 191: 131–139.CrossRefGoogle ScholarPubMed
24.Fleischhacker, WW, McQuade, RD, Marcus, RN, etal. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry. 2009; 65: 510–517.CrossRefGoogle ScholarPubMed
25.Samalin, L, Garnier, M, Llorca, P-M. Clinical potential of lurasidone in the management of schizophrenia. Ther Clin Risk Manag. 2011; 7: 239–250.CrossRefGoogle ScholarPubMed
26.Glassman, AH, Bigger, JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001; 158(11): 1774–1782.CrossRefGoogle ScholarPubMed
27.Strom, BL, Eng, SM, Faich, G, etal. Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Am J Psychiatry. 2011; 168: 193–201.CrossRefGoogle Scholar
28.U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for industry: QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. October 2005. Available at: www.fda.gov/downloads/RegulatoryInformation/ucm129357.pdf. Accessed December 5, 2012.Google Scholar